• 1. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 2. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 3. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

Ethyl 3-bromo-4-ethoxybenzoate (CAS No. 875846-59-6): A Comprehensive Overview

Ethyl 3-bromo-4-ethoxybenzoate (CAS No. 875846-59-6) is a specialized organic compound that has garnered significant attention in the field of pharmaceutical research and chemical synthesis. This compound, characterized by its unique structural and functional properties, plays a pivotal role in the development of various therapeutic agents and biochemical studies. The Ethyl 3-bromo-4-ethoxybenzoate molecule, featuring a bromine substituent at the third position and an ethoxy group at the fourth position of the benzoate backbone, offers a versatile platform for further chemical modifications and biological evaluations.

The significance of this compound is underscored by its applications in synthetic organic chemistry, where it serves as a key intermediate in the preparation of more complex molecules. The presence of both bromine and ethoxy groups provides distinct reactivity patterns, making it a valuable building block for constructing intricate molecular architectures. In recent years, the demand for such intermediates has surged due to their utility in drug discovery programs aimed at identifying novel pharmacophores with enhanced efficacy and reduced side effects.

Recent advancements in medicinal chemistry have highlighted the importance of benzoate derivatives in the development of new therapeutic interventions. The Ethyl 3-bromo-4-ethoxybenzoate has been extensively studied for its potential role in modulating various biological pathways. For instance, researchers have explored its interactions with enzymes and receptors involved in inflammatory responses, suggesting its potential as an anti-inflammatory agent. Additionally, preliminary studies have indicated that this compound may exhibit antioxidant properties, which could be beneficial in combating oxidative stress-related diseases.

The structural features of Ethyl 3-bromo-4-ethoxybenzoate make it an attractive candidate for further derivatization. The bromine atom at the third position allows for electrophilic aromatic substitution reactions, enabling the introduction of additional functional groups such as amines or thiols. Similarly, the ethoxy group at the fourth position can be selectively modified through nucleophilic aromatic substitution or oxidation reactions. These chemical handles facilitate the synthesis of a wide range of analogs, each with distinct biological activities that can be fine-tuned to optimize therapeutic outcomes.

In the realm of computational chemistry, Ethyl 3-bromo-4-ethoxybenzoate has been employed in virtual screening campaigns to identify potential drug candidates. High-throughput virtual screening (HTVS) techniques have been used to dock this compound against various protein targets, including kinases and transcription factors. The results have revealed promising interactions with several disease-related proteins, paving the way for structure-based drug design strategies.

The synthesis of Ethyl 3-bromo-4-ethoxybenzoate typically involves multi-step organic transformations starting from commercially available precursors. A common synthetic route begins with the bromination of 4-methoxybenzoic acid followed by esterification to yield Ethyl 3-bromo-4-methoxybenzoate. Subsequent methylation and bromination steps convert this intermediate into the desired product. These synthetic methodologies have been optimized to ensure high yields and purity, making them suitable for industrial-scale production.

The chemical properties of Ethyl 3-bromo-4-ethoxybenzoate are further influenced by its solubility characteristics. Being a benzoate ester, it exhibits moderate solubility in organic solvents such as dichloromethane and ethyl acetate but limited solubility in water. This solubility profile impacts its formulation as an active pharmaceutical ingredient (API) and necessitates careful consideration during drug development processes.

Regulatory considerations play a crucial role in the commercialization of Ethyl 3-bromo-4-ethoxybenzoate. Compliance with Good Manufacturing Practices (GMP) ensures that the compound is produced under controlled conditions to meet stringent quality standards. Additionally, toxicological studies are conducted to assess its safety profile before it can be approved for use in pharmaceutical formulations.

The future prospects of Ethyl 3-bromo-4-ethoxybenzoate are promising, with ongoing research exploring its potential applications beyond traditional pharmaceuticals. For instance, its incorporation into materials science applications has been investigated due to its ability to form stable complexes with metal ions. These complexes exhibit unique catalytic properties that could be leveraged in industrial processes.

In conclusion, Ethyl 3-bromo-4-ethoxybenzoate (CAS No. 875846-59-6) is a multifaceted compound with significant implications in pharmaceutical research and chemical synthesis. Its unique structural features and reactivity patterns make it a valuable tool for developing novel therapeutic agents and biochemical probes. As research continues to uncover new applications for this compound, its importance in advancing scientific knowledge and innovation is likely to grow.

• 536974-76-2(2-bromo-4-(hydroxymethyl)phenyl benzoate)
• 149517-92-0(Ethyl 4-bromo-3,5-diethoxybenzoate)
• 128401-55-8(Ethyl 4-acetoxy-3-bromobenzoate)
• 536974-75-1(2-bromo-4-formylphenyl benzoate)
• 149817-68-5(Methyl 4-acetoxy-3-bromobenzoate)
• 158585-09-2(Benzyl 3,5-bis(benzyloxy)-4-bromobenzoate)
• 460079-82-7(Ethyl 3-bromo-4-methoxybenzoate)
• 60568-32-3(Benzoic acid, 3,5-dibromo-4-(2-hydroxyethoxy)-, 2-hydroxyethyl ester)
• 860695-33-6(Ethyl 3-bromo-4-propoxybenzoate)
• 860695-52-9(Ethyl 3-bromo-4-isopropoxybenzoate)